{"organizations": [], "uuid": "46b11d98260e14059a75b9b1e429bfe10fb66993", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-genomic-health-reports-q4-earnings/brief-genomic-health-reports-q4-earnings-per-share-0-05-idUSL5N1QQ860", "country": "US", "domain_rank": 408, "title": "BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-09T01:04:00.000+02:00", "replies_count": 0, "uuid": "46b11d98260e14059a75b9b1e429bfe10fb66993"}, "author": "", "url": "https://www.reuters.com/article/brief-genomic-health-reports-q4-earnings/brief-genomic-health-reports-q4-earnings-per-share-0-05-idUSL5N1QQ860", "ord_in_thread": 0, "title": "BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "reuters) - genomic health inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Genomic Health Inc:\n* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK\n* SEES 2018 REVENUE FROM $ 366 MILLION TO $382 MILLION * GENOMIC HEALTH INC - SEES 2018 GAAP BASIC EPS OF $0.00 TO $0.14\n* GENOMIC HEALTH - ‍WILL NO LONGER PROVIDE ONCOTYPE SEQ LIQUID SELECT TEST OR FURTHER INVEST IN NON-PROPRIETARY NGS-BASED PANELS​\n* GENOMIC HEALTH INC - SEES 2018 NON-GAAP BASIC EPS IN RANGE OF $0.39 TO $0.56\n* Q4 EARNINGS PER SHARE VIEW $0.07, REVENUE VIEW $88.9 MILLION — THOMSON REUTERS I/B/E/S\n* ‍WILL REDUCE POSITIONS BY ABOUT 10 PERCENT & TAKE A CHARGE OF ABOUT $10 MILLION IN Q1​\n* FY2018 EARNINGS PER SHARE VIEW $0.34, REVENUE VIEW $383.8 MILLION — THOMSON REUTERS I/B/E/S\n* GENOMIC HEALTH - IN 2018, PLANS TO DIRECT RESOURCES TO EXPAND ITS ONCOTYPE DX OFFERING\n* GENOMIC HEALTH - TO NO LONGER PROVIDE ONCOTYPE SEQ LIQUID SELECT TEST/FURTHER INVEST IN NON-PROPRIETARY NEXT-GENERATION SEQUENCING (NGS)-BASED PANELS\n* IN CONNECTION TO THE SHIFT IN FOCUS, CO WILL REDUCE POSITIONS BY ABOUT 10 PERCENT\n* GENOMIC HEALTH-TO TAKE CHARGE OF ABOUT $10 MILLION IN Q1 FOR COSTS WITH PERSONNEL REDUCTIONS&WRITE-OFF OF CERTAIN ASSETS ASSOCIATED WITH NGS-BASED PANELS Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": [], "published": "2018-03-09T01:04:00.000+02:00", "crawled": "2018-03-09T01:17:39.002+02:00", "highlightTitle": ""}